Prudential PLC boosted its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 427.4% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,393 shares of the life sciences company’s stock after purchasing an additional 3,560 shares during the quarter. Prudential PLC’s holdings in Illumina were worth $1,318,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Proficio Capital Partners LLC increased its holdings in Illumina by 61.7% during the 4th quarter. Proficio Capital Partners LLC now owns 97 shares of the life sciences company’s stock worth $29,000 after purchasing an additional 37 shares during the period. Moody National Bank Trust Division purchased a new position in Illumina during the 4th quarter worth $31,000. Virtus ETF Advisers LLC purchased a new position in Illumina during the 4th quarter worth $31,000. Oregon Public Employees Retirement Fund increased its holdings in Illumina by 66,581.4% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 10,562,335 shares of the life sciences company’s stock worth $35,000 after purchasing an additional 10,546,495 shares during the period. Finally, Arcadia Investment Management Corp MI purchased a new position in Illumina during the 4th quarter worth $39,000. Institutional investors own 89.25% of the company’s stock.
Shares of NASDAQ ILMN opened at $309.84 on Friday. The company has a current ratio of 2.49, a quick ratio of 2.27 and a debt-to-equity ratio of 0.23. The firm has a market cap of $45.55 billion, a price-to-earnings ratio of 54.17, a P/E/G ratio of 2.17 and a beta of 1.18. Illumina, Inc. has a 12-month low of $225.82 and a 12-month high of $372.61.
ILMN has been the topic of several research reports. Morgan Stanley reduced their price objective on Illumina from $320.00 to $288.00 and set an “equal weight” rating on the stock in a report on Monday, January 7th. BidaskClub raised Illumina from a “sell” rating to a “hold” rating in a research report on Wednesday, February 13th. Zacks Investment Research cut Illumina from a “buy” rating to a “hold” rating in a research report on Monday, December 31st. Deutsche Bank cut Illumina from a “buy” rating to a “hold” rating and set a $296.53 target price on the stock. in a research report on Friday, January 25th. Finally, Bank of America reaffirmed a “buy” rating and set a $355.00 target price on shares of Illumina in a research report on Wednesday, January 30th. Four analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Illumina presently has an average rating of “Buy” and an average price target of $345.82.
In other news, Director Jay T. Flatley sold 3,300 shares of the firm’s stock in a transaction on Wednesday, December 26th. The stock was sold at an average price of $273.87, for a total value of $903,771.00. Following the completion of the sale, the director now owns 339,879 shares of the company’s stock, valued at approximately $93,082,661.73. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Karin Eastham sold 5,000 shares of the firm’s stock in a transaction on Wednesday, January 2nd. The stock was sold at an average price of $294.08, for a total value of $1,470,400.00. Following the completion of the sale, the director now directly owns 12,655 shares of the company’s stock, valued at approximately $3,721,582.40. The disclosure for this sale can be found here. Insiders sold a total of 35,526 shares of company stock valued at $10,501,041 in the last three months. Insiders own 0.54% of the company’s stock.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Featured Story: Bid-Ask Spread
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.